A brief history of the development of antidepressant drugs: from monoamines to glutamate.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Experimental and clinical psychopharmacology

• Publication date

  2015-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1037/a0038550PMID 25643025PMCID PMC4428540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

  2014cited by this paper
• D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression

  2014cited by this paper
• Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.

  2014influential reference
• Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response

  2014cited by this paper
• Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.

  2014cited by this paper
• Riluzole likely lacks antidepressant efficacy in ketamine non-responders.

  2014cited by this paper
• Clinical predictors of ketamine response in treatment-resistant major depression.

  2014cited by this paper
• Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.

  2014cited by this paper
• Do the dissociative side effects of ketamine mediate its antidepressant effects?

  2014cited by this paper
• EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION

  2014cited by this paper
• Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

  2014cited by this paper
• Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression.

  2014influential reference
• Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression.

  2014cited by this paper
• A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

  2014cited by this paper
• Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation.

  2014cited by this paper
• Vortioxetine for the Treatment of Depression

  2014cited by this paper
• A randomized controlled trial of intranasal ketamine in major depressive disorder.

  2014cited by this paper
• Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine

  2014cited by this paper
• GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists

  2014cited by this paper
• Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment.

  2013cited by this paper
• Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects.

  2013cited by this paper
• Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date

  2013cited by this paper
• A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

  2013cited by this paper
• A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.

  2013cited by this paper
• Vortioxetine: First Global Approval

  2013cited by this paper
• GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects

  2013cited by this paper
• The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor

  2013cited by this paper
• Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression.

  2013cited by this paper
• Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus.

  2013cited by this paper
• Serial infusions of low-dose ketamine for major depression

  2013cited by this paper
• Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report.

  2013cited by this paper
• Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

  2013influential reference
• Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.

  2013influential reference
• Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.

  2013cited by this paper
• Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

  2013cited by this paper
• Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

  2013cited by this paper
• Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

  2013influential reference
• Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

  2013cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013influential reference
• Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression

  2013cited by this paper
• Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial

  2013cited by this paper
• Targeting the Glutamatergic System to Treat Major Depressive Disorder

  2012cited by this paper
• A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

  2012cited by this paper
• Compounded oral ketamine.

  2012cited by this paper
• Memantine for late‐life depression and apathy after a disabling medical event: a 12‐week, double‐blind placebo‐controlled pilot study

  2012cited by this paper
• Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

  2012influential reference
• A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

  2012cited by this paper
• Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

  2012cited by this paper
• Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States

  2012cited by this paper
• The prevalence and natural history of urinary symptoms among recreational ketamine users

  2012cited by this paper
• Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

  2012cited by this paper
• The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder

  2011cited by this paper
• Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression.

  2011cited by this paper
• The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

  2011cited by this paper
• NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses

  2011cited by this paper
• Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.

  2011cited by this paper
• Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

  2011cited by this paper
• Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance

  2010influential reference
• Altered expression of glutamate signaling, growth factor and glia genes in the locus coeruleus of patients with major depression

  2010cited by this paper
• Depression research: where are we now?

  2010cited by this paper
• Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

  2010cited by this paper
• Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care

  2010cited by this paper
• Taming the Ketamine Tiger

  2010cited by this paper
• A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

  2010cited by this paper
• Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

  2010cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010cited by this paper
• Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

  2009cited by this paper
• The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression

  2009influential reference
• Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

  2009cited by this paper
• Serotonin Norepinephrine Reuptake Inhibitors: Spectrum of Efficacy in Major Depressive Disorder

  2009cited by this paper
• The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders

  2009cited by this paper
• Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response.

  2009influential reference
• Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression.

  2009influential reference
• Reduced Prefrontal Glutamate/Glutamine and γ-Aminobutyric Acid Levels in Major Depression Determined Using Proton Magnetic Resonance Spectroscopy

  2008influential reference
• An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

  2008cited by this paper
• Lamina-Specific Abnormalities of NMDA Receptor-Associated Postsynaptic Protein Transcripts in the Prefrontal Cortex in Schizophrenia and Bipolar Disorder

  2008cited by this paper
• Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics.

  2008cited by this paper
• Tolerability of modern antidepressants.

  2008cited by this paper
• Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

  2008cited by this paper
• Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy.

  2007cited by this paper
• Increased levels of glutamate in brains from patients with mood disorders.

  2007cited by this paper
• Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.

  2007cited by this paper
• Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors.

  2007cited by this paper
• Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.

  2007cited by this paper
• Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders

  2007influential reference
• Tackling Adolescent Substance Abuse in Hong Kong: Where We Should and Should Not Go

  2007cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• 5-Year Trends in Use of Hallucinogens and Other Adjunct Drugs among UK Dance Drug Users

  2006cited by this paper
• A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

  2006influential reference
• A double-blind, placebo-controlled study of memantine in the treatment of major depression.

  2006influential reference
• In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors.

  2006cited by this paper
• Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.

  2006cited by this paper
• Alzheimer disease: progress or profit?

  2006cited by this paper
• GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.

  2005cited by this paper
• Case history: the discovery of fluoxetine hydrochloride (Prozac).

  2005cited by this paper
• Elevated Levels of the NR2C Subunit of the NMDA Receptor in the Locus Coeruleus in Depression

  2005influential reference
• Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression

  2005cited by this paper
• 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

  2005cited by this paper
• Ionotropic and metabotropic glutamate receptor structure and pharmacology

  2005influential reference
• The Discovery of Fluoxetine Hydrochloride (Prozac)

  2005cited by this paper

• Vortioxetine: A comprehensive profile.

  2026cites this paper
• Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data.

  2026cites this paper
• EcoHIV Infection Disrupts Dopamine and Serotonin Transporter Function, Altering Release Dynamics in C57BL/6J Mice

  2026cites this paper
• Pharmacological treatment of adolescent depression: Current advances and future perspectives

  2026cites this paper
• From metabolism to mood regulation: astrocytes as a driver of depression

  2026cites this paper
• Puerarin's multidimensional antidepressant action: decoding the gut-liver-brain axis through gut microbiota, hepatic homeostasis, and neuroimmune regulation.

  2026cites this paper
• Non-implantable neuromodulation therapies compared to conventional treatments for major depression

  2026cites this paper
• Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials

  2026cites this paper
• Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence

  2026cites this paper
• Dose-dependent pharmacological mechanisms within the Neuroscience-based Nomenclature: a new concept to facilitate neuroscience-based prescribing.

  2026cites this paper
• The C2H2-GGAT Regulatory Module Fine-Tunes Glutamate Homeostasis to Improve Fruit Flavour and Enhance Disease Resistance in Peach.

  2026cites this paper
• [Efficacy and safety of Cortexin as additional therapy in patients with depressive disorder].

  2026cites this paper
• Assessing adult zebrafish despair-like behaviors in the small vertical cylinder immobility test (VCIT).

  2025cites this paper
• Addressing the serotonin hypothesis of depression through analyses of genetics, methylation and metabolite variations in glioma patients

  2025cites this paper
• Antidepressant effects of ershiwei roudoukou pills and its active ingredient Macelignan: Multiple mechanisms involving oxidative stress, neuroinflammation and synaptic plasticity

  2025cites this paper
• Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine

  2025cites this paper
• Protective effect of morin hydrate against chronic unpredictable mild stress-induced depression in mice

  2025cites this paper
• Five-Year Trends in SSRI Consumption: A Precision Medicine Approach to Comparative Analysis Between Serbia and European Countries

  2025cites this paper
• Psychotropic Medications for Non-Psychiatric Conditions: A Narrative Review

  2025cites this paper
• Beneficial and harmful effects of duloxetine versus placebo, ‘active placebo’ or no intervention for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

  2025cites this paper
• Current Progress in Targeted Pharmacotherapy to Treat Symptoms of Major Depressive Disorder: Moving From Broad-Spectrum Treatments to Precision Psychiatry.

  2025cites this paper
• Environmental antibiotic emissions and their residual impact on livestock farming

  2025cites this paper
• Pharmaco-Multiomics: A New Frontier in Precision Psychiatry

  2025cites this paper
• There's More Than One Way to Bring Health Back: Divergent Effects of Psilocybin and Escitalopram Treatment on Emotional Brain Function in Depression.

  2025cites this paper
• Effects of Selective Serotonin Reuptake Inhibitors (SSRI) on the Placenta†.

  2025cites this paper
• Efficacy of Paroxetine in Treating Depression Across Different Demographics: A Literature Review

  2025cites this paper
• MAO inhibitors for treatment-resistant depression: bringing an updated perspective on pioneering drugs.

  2025cites this paper
• α2C Adrenoceptor antagonist KMCA-0011 alleviated depressive-like behaviors in a maternal separation mouse model.

  2025cites this paper
• Direct and spillover promotional effects on drug prescriptions: Comparing differential physician- vs. patient-focused promotional effects

  2025cites this paper
• Exploring the Impact and Mechanisms of Coffee and Its Active Ingredients on Depression, Anxiety, and Sleep Disorders

  2025cites this paper
• GPR120 internalization: a key mechanism for EPA in antidepressant action.

  2025cites this paper
• Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review.

  2025cites this paper
• Relationships Between Clinical Psychological Depression and Employee Absenteeism

  2025cites this paper
• An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression

  2025cites this paper
• Rapid-Acting Treatments for Perinatal Depression: Clinical Landscapes and Future Horizons

  2025cites this paper
• Ferulic Acid in Chaihu Shugan San Modulates Depression-like Behavior, Endothelial and Gastrointestinal Dysfunction in Rats via the Ghrl-Edn1/Mecp2/P-mTOR/VEGFA Pathway: A Multi-Omics Study.

  2025cites this paper
• Disruption of the Placenta–Brain Axis in Transgenic Mice Lacking Serotonin Transporter (SERT) in Trophoblast Cells

  2025cites this paper
• Beyond Depression: The Role of Antidepressants in Managing Chronic Temporomandibular Disorders. A Systematic Review

  2025cites this paper
• Neuropharmacology of Ketamine and Its Use in the Treatment of Major Depressive Disorder: A Review

  2025cites this paper
• An Updated Review on the Complex Association of Cardiovascular Disease (CVD) and Depression.

  2025cites this paper
• Ganoderma lucidum: An Emerging Nutritional Approach to Manage Depression

  2025influential citation
• Pharmacological and resting state fMRI reveal Osteocalcin’s effects on mouse brain regions with high Gpr37 and Gpr158 expression

  2025cites this paper
• Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria

  2025cites this paper
• Comparative Efficacy and Safety of Ketamine Versus Electroconvulsive Therapy in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.

  2025cites this paper
• Effects of tianeptine on mTORC1-mediated neuronal autophagy in primary rat hippocampal neurons under nutrient deprivation

  2025cites this paper
• Predicting the treatment outcomes of major depressive disorder interventions with baseline resting-state functional connectivity: a meta-analysis

  2025cites this paper
• Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

  2025cites this paper
• Understanding Target-Specific Effects of Antidepressant Drug Pollution on Molluscs: A Systematic Review Report

  2025cites this paper
• Prophylactic administration of Xuesaitong soft capsule ameliorating depression-like behaviors in rats after ischemic stroke by modulating metabolic disturbance.

  2025cites this paper
• Is poor dose selection undermining the translational validity of antidepressant research involving animal models?

  2025cites this paper
• Fluoxetine exerts anti-proliferative effect in human epidermal keratinocytes

  2025cites this paper
• Speech-Based Depression Recognition in Hikikomori Patients Undergoing Cognitive Behavioral Therapy

  2025cites this paper
• (S)-ketamine augments behavioral and physiological responses to Δ9-tetrahydrocannabinol

  2025cites this paper
• From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation

  2025cites this paper
• Comparison between Cannabidiol and Fluoxetine effects on chronic neuropathic pain and depression comorbid in rats

  2025influential citation
• Assessing the Impact of Antidepressants on Cancer Treatment: A Retrospective Analysis of 14 Antineoplastic Agents.

  2025cites this paper
• Updates on first- and second-generation antidepressants used in the treatment of traumatic brain injury-induced depression.

  2025cites this paper
• Ketamine infusion therapy for treatment-resistant major depressive disorder and suicidal ideation: Nursing care and considerations.

  2025cites this paper
• Autophagy Modulation by Antidepressants: Mechanisms and Implications

  2025cites this paper
• Monoamine oxidase and neurodegeneration: mechanisms, inhibitors and natural compounds for therapeutic intervention.

  2024cites this paper
• Antidepressant Efficacy in Managing Nonspecific Chronic Lower Back Pain Among Older Adults: A Review

  2024cites this paper
• Transport and inhibition mechanisms of the human noradrenaline transporter

  2024cites this paper
• Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov

  2024cites this paper
• The emergence of antidepressant drugs targeting GABAA receptors: A concise review.

  2024cites this paper
• Activation syndrome in children and adolescents treated with selective serotonin reuptake inhibitors.

  2024cites this paper
• The rapid antidepressant effect of acupuncture on two animal models of depression by increasing the expression of synaptic proteins in the prefrontal cortex

  2024cites this paper
• Environmentally relevant concentrations of the tricyclic antidepressant, amitriptyline, affect feeding and reproduction in a freshwater mollusc.

  2024cites this paper
• A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers

  2024cites this paper
• Toxin-derived peptides: An unconventional approach to alleviating cerebral stroke burden and neurobehavioral impairments.

  2024cites this paper
• New insights about the antidepressant-like effects of riparin A in a chronic murine model of depression

  2024cites this paper
• Six-compound combo remedy ameliorates corticosterone-induced depressive behaviors in mice via targeting HTR1A signaling.

  2024cites this paper
• Role of Glial Cells in Neuronal Function, Mood Disorders, and Drug Addiction

  2024cites this paper
• Funding of Clinical Trials and Reported Drug Efficacy

  2024cites this paper
• Subanesthetic Ketamine Suppresses Locus Coeruleus–Mediated Alertness Effects: A 7T fMRI Study

  2024cites this paper
• Chronic disease management via modulation of cellular signaling by phytoestrogen Bavachin

  2024cites this paper
• Prediction of antidepressant side effects in the Genetic Link to Anxiety and Depression Study

  2024cites this paper
• Acute 2-phenyl-3-(phenylselanyl)benzofuran treatment reverses the neurobehavioral alterations induced by sleep deprivation in mice.

  2024cites this paper
• New insights into the involvement of serotonin and BDNF-TrkB signalling in cannabidiol's antidepressant effect.

  2024cites this paper
• Participation of Ca2+-Calmodulin–Dependent Protein Kinase II in the Antidepressant-Like Effects of Melatonin

  2024cites this paper
• Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview

  2024cites this paper
• Lifestyle factors and BMI attenuate relationships between biomarkers of inflammation and depressive symptoms and well-being: A cross-sectional study

  2024cites this paper
• Temperature-dependent toxicity of fluoxetine alters the thermal plasticity of marine diatoms.

  2024cites this paper
• Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding

  2024cites this paper
• Genetically encoded sensors for in vivo detection of neurochemicals relevant to depression

  2024cites this paper
• The role of serotonin in depression—A historical roundup and future directions

  2024cites this paper
• Role of Serotonylation and SERT Posttranslational Modifications in Alzheimer's Disease Pathogenesis

  2024cites this paper
• A Review of Psychopharmacology for the Management of Depression and Anxiety in Children and Adolescents

  2024cites this paper
• Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances

  2024cites this paper
• Recording the brain in vivo: emerging technologies for the exploration of mental health conditions.

  2024cites this paper
• The Effects of Selective Serotonin Reuptake Inhibitors on Motility of Peripheral Smooth Muscles

  2024cites this paper
• Therapeutic potential and mechanisms of stem cells in major depressive disorder: a comprehensive review

  2024cites this paper
• Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies

  2024influential citation
• Metabolic bioactivation of antidepressants: advance and underlying hepatotoxicity

  2024cites this paper
• Major depressive disorder: hypothesis, mechanism, prevention and treatment

  2024cites this paper
• Anti-oxidant and neuro-modulatory effects of bioactive Byttneria pilosa leaf extract in swiss albino mice using behavioral models

  2024cites this paper
• Fears Worth Testing Out: A Systematic Review of the Neural Mechanisms of Treatment Outcome for Anxiety-Related Disorders.

  2024cites this paper
• Biocatalysis for the Synthesis of Active Pharmaceutical Ingredients in Deep Eutectic Solvents: State-of-the-Art and Prospects

  2024cites this paper
• A Retrospective Case–Control Study on the Differences in the Effectiveness of Theta-Burst Stimulation Therapy for Depression with and without Antidepressant Medication

  2024cites this paper
• The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies.

  2024cites this paper
• Early Life Stress and Major Depressive Disorder—An Update on Molecular Mechanisms and Synaptic Impairments

  2024cites this paper